Biosig Technologies Inc (BSGM)

[Boredoftv]

BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued a Letter to Shareholders providing highlights on the Company's recent developments and updates.

Recent Company highlights include:

Updates on the commercial adoption of the PURE EPâ?¢ System, including the first commercial sale of three units to St. David's HealthCare in Austin, TX, an HCA Healthcare-owned hospital.
More than 643 patient cases have been conducted with the PURE EPâ?¢ System by 40 physicians across eight clinical sites to date.
At least three more clinical sites are scheduled to commence the evaluation in the coming months, including the New York-Presbyterian/Weill Cornell Medical Center and the Michigan Medicineâ??University Hospital that maintain two of the most extensive electrophysiology programs in the country.
The PURE EPâ?¢ System received favorable reviews during leading industry conferences, including EPLive 2020 and the 26th Annual International AF Symposium 2021. Complete recordings of the presentations and articles authored by the physician users and independent reviewers of the technology are available on the Company's website.
The Company launched an initiative to develop and commercialize novel AI- and machine learning-powered software solutions. The program will be conducted under the leadership of Mayo Clinic and Dr. Alexander Wissner-Gross, a leading AI scientist at M.I.T.
The Company deployed innovative Vuzix M400 Smart Glasses for remote servicing and training, allowing its customers uninterrupted access to its technical team.
The NeuroClearâ?¢ division is developing a novel nerve sensing and stimulation technology to improve current treatments for resistant hypertension and other nerve-related therapeutic targets.
The Company reports $28.3 million in cash as of December 31, 2020, positioning the Company well for commercial and operational growth, based on the Company's current expectations and projections.
"We made some significant strides in 2020, which have laid the foundation for a strong 2021," stated Kenneth L. Londoner, Founder, Chairman, and CEO of BioSig Technologies, Inc. "Commercial adoption of the PURE EPâ?¢ System is gaining momentum, and we continue to add new healthcare facilities and complete more patient cases. Commercialization, innovation, and growth remain at the forefront of our strategic priorities as we expand our clinic footprint and strengthen our product positions and service offerings. We have a strong balance sheet, we are progressing well with our neurostimulation division, and are looking to the future of next-generation AI- and machine learning-powered software for our PURE EPâ?¢ System with a new strategic initiative that we are launching with the Mayo Foundation for Medical Education and Research. BioSig is well-positioned to have an excellent 2021, and we look forward to executing on many opportunities that we believe will drive shareholder value."

To view the Company's Shareholder Letter in its entirety, please visit https://ir.biosig.com.